Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

PolyPeptide appoints new directors and removes transfer and voting restrictions

At the extraordinary general meeting, shareholders approved all proposals from the board and elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong to the board of directors; John Chongbo Rim will serve as president. Transfer and voting restrictions were also removed from the articles of association. The resolutions take effect in connection with the public tender offer by Samsung Peptide; Samsung Biologics currently holds 87.92 percent, but the completion of the takeover has been postponed to the end of 2026 or the first quarter of 2027 due to regulatory uncertainties. » More on finanzen.net
PolyPeptide investment five years ago would have incurred a 63.21% loss

A CHF 100 investment in PolyPeptide five years ago would today amount to 0.833 shares and would have been worth CHF 36.79 on 22 October 2026 (share price CHF 44.15), representing a decline of 63.21%. PolyPeptide is valued at CHF 1.45 billion on the market. The stock made its market debut on 29 April 2021 with an initial price of CHF 72.50. » More on finanzen.net
PolyPeptide: one-year return of 71.48% on investment made one year ago

If 1,000 CHF had been invested in PolyPeptide one year ago (price 25.60 CHF), the value on 08.10.2026 would be 1,714.84 CHF (price 43.90 CHF), representing a gain of 71.48%. The most recently reported market value is 1.45 billion CHF. Stock splits and dividends were not taken into account in the calculation. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2022, POLYPEPTIDE GROUP SF -,01 has already paid €0.29 in dividends. The last payout was in May 2022.

Financials

In the last quarter, POLYPEPTIDE GROUP SF -,01 had revenue of €236.24m and net profit of €9.07m

(EUR)	June 2026	YoY
Revenue	236.24m	-
Gross profit	53.33m	-
Net profit	9.07m	-
EBITDA	38.76m	-

Fundamentals

Metric	Value
Market capitalization	€1.56bn
Number of shares	33.02m
52-week high/low	€54.36 - €15.43
Dividends	No
Beta	1.00
P/E ratio	109.70
PEG ratio	0.41
P/B ratio	4.42
P/S ratio	3.39

Company profile

PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.